| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Obstetrics, Gynecology, and Women’s Health, University of Louisville School of Medicine, Louisville, KY 40202
Exosome release by viable cells is a feature of activated cell types, including tumors, fetal cells, and cells of the immune system. Exosomes critically regulate immune activation, by mediating activation-induced cell death. Fetal cells may mimic these events to selectively delete reactive lymphocytes. In this study the presence and composition of placenta-derived exosomes are demonstrated in the maternal circulation along with their consequences on T cell activation markers. For all pregnant patients, exosomes were isolated from sera obtained between 28 and 30 wk gestation. For pregnant women, subsequently delivering at term, circulating levels of placental exosomes were 1.8 times greater than those delivering preterm (p < 0.0001). Exosomes isolated from pregnancies subsequently delivering at term expressed significantly higher levels of biologically active components, including Fas ligand (FasL) and HLA-DR, than those from pregnancies delivering preterm. Standardizing for protein concentrations, exosomes from term-delivering pregnancies exhibited greater suppression of CD3-
and JAK3 than those delivering preterm. The suppression of CD3- and JAK3 correlated with exosome expression levels of FasL (r2 = 0.92 and r2 = 0.938, respectively). Fractionation of exosomes from term-delivering pregnancies by continuously eluting electrophoresis indicated that intact 42kD FasL and an unidentified 24-kDa protein were associated with CD3- suppression. Our results demonstrated that exosomes from pregnancies ultimately delivering at term are present at significantly greater concentrations than those from pregnancies delivering preterm; however, exosomes from term-delivering pregnancies also exhibit significantly greater suppression of CD3- and JAK3.
This article has been cited by other articles:
|
|
 |
|
  N. Gasper-Smith, D. M. Crossman, J. F. Whitesides, N. Mensali, J. S. Ottinger, S. G. Plonk, M. A. Moody, G. Ferrari, K. J. Weinhold, S. E. Miller, et al. Induction of Plasma (TRAIL), TNFR-2, Fas Ligand, and Plasma Microparticles after Human Immunodeficiency Virus Type 1 (HIV-1) Transmission: Implications for HIV-1 Vaccine Design J. Virol., August 1, 2008; 82(15): 7700 - 7710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Montecalvo, W. J. Shufesky, D. Beer Stolz, M. G. Sullivan, Z. Wang, S. J. Divito, G. D. Papworth, S. C. Watkins, P. D. Robbins, A. T. Larregina, et al. Exosomes As a Short-Range Mechanism to Spread Alloantigen between Dendritic Cells during T Cell Allorecognition J. Immunol., March 1, 2008; 180(5): 3081 - 3090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Kim, N. R. Bianco, W. J. Shufesky, A. E. Morelli, and P. D. Robbins MHC Class II+ Exosomes in Plasma Suppress Inflammation in an Antigen-Specific and Fas Ligand/Fas-Dependent Manner J. Immunol., August 15, 2007; 179(4): 2235 - 2241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Admyre, S. M. Johansson, K. R. Qazi, J.-J. Filen, R. Lahesmaa, M. Norman, E. P. A. Neve, A. Scheynius, and S. Gabrielsson Exosomes with Immune Modulatory Features Are Present in Human Breast Milk J. Immunol., August 1, 2007; 179(3): 1969 - 1978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Valenti, V. Huber, P. Filipazzi, L. Pilla, G. Sovena, A. Villa, A. Corbelli, S. Fais, G. Parmiani, and L. Rivoltini Human Tumor-Released Microvesicles Promote the Differentiation of Myeloid Cells with Transforming Growth Factor-{beta}-Mediated Suppressive Activity on T Lymphocytes. Cancer Res., September 15, 2006; 66(18): 9290 - 9298. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
